Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2406990 | Vaccine | 2008 | 9 Pages |
Abstract
NYVAC-C (vP2010), a recombinant vector expressing HIV subtype C gag, pol, env and nef antigens, was tested in a phase I study in healthy, HIV negative volunteers in London and Lausanne. Twenty-four participants were randomised to receive NYVAC-C (20) or matching placebo (4) at weeks 0 and 4, and assessed for safety and immunogenicity over 48 weeks. There were no serious adverse events, and no clinical or laboratory abnormalities or other events that led to withdrawal, interruption or dose reduction of the NYVAC-C/placebo. Half of the 10 assessed responded in the ELISpot assay under stringent criteria, which informed the sample size for a DNA–NYVAC-C comparison to NYVAC-C alone.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Pierre-Alexandre Bart, Ruth Goodall, Tristan Barber, Alexandre Harari, Ana Guimaraes-Walker, Mona Khonkarly, Neil C. Sheppard, Yolanda Bangala, Marie-Joelle Frachette, Ralf Wagner, Peter Liljeström, Jean-Pierre Kraehenbuhl, Marc Girard, Jaap Goudsmit,